GLP-1 cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop

Diabetes

Volumn 64, Issue 9, 2015, Pages 3273-3284

  Giacco, Ferdinando ^a   Du, Xueliang ^a   Carratu, Anna ^b   Gerfen, Gary J ^a   D'Apolito, Maria ^c   Giardino, Ida ^c   Rasola, Andrea ^d   Marin, Oriano ^d   Divakaruni, Ajit S ^e   Murphy, Anne N ^e   Shah, Manasi S ^a   Brownlee, Michael ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e San Diego   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 1 [28-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HEMOGLOBIN A1C; IRON; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROSTACYCLIN SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL; GLUCAGON-LIKE PEPTIDE-1 (9-36)-AMIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG HALF LIFE; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL DIABETES MELLITUS; FEEDBACK SYSTEM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANALOGS AND DERIVATIVES; CELL LINE; METABOLISM; MITOCHONDRION;

CELL LINE; DIABETES COMPLICATIONS; ENDOTHELIAL CELLS; FEEDBACK, PHYSIOLOGICAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; IRON; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; PEPTIDES; REACTIVE OXYGEN SPECIES;

EID: 84960144959     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0084     Document Type: Article

References (51)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329: 977-986
2. 1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-983
3. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited. Diabetes 2008;57:995-1001
4. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006;29: 2433-2438
5. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708
6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070
7. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 1997;416:15-18
8. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bio-energ Biomembr 2008;40:171-182
9. Medina M, Garrido JJ, Wandosell FG. Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Front Mol Neurosci 2011;4:24
10. Medina M, Wandosell F. Deconstructing GSK-3: the fine regulation of its activity. Int J Alzheimers Dis 2011;2011:479249
11. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005;65:10545-10554
12. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011;167:177-184
13. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J Neurosci 2012;32:13701-13708
14. Chiara F, Castellaro D, Marin O, et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PloS One 2008;3:e1852
15. D'Apolito M, Du X, Zong H, et al. Urea-induced ROS generation causes insulin resistance in mice with chronic renal failure. J Clin Invest 2010;120:203-213
16. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-790
17. Srinivasan C, Liba A, Imlay JA, Valentine JS, Gralla EB. Yeast lacking superoxide dismutase(s) show elevated levels of "free iron" as measured by whole cell electron paramagnetic resonance. J Biol Chem 2000;275:29187-29192
18. Okabe J, Orlowski C, Balcerczyk A, et al. Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circ Res 2012;110:1067-1076
19. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006;116:1071-1080
20. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009;417:1-13
21. Adam-Vizi V, Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 2006;27:639-645
22. Hardt SE, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 2002;90:1055-1063
23. Ugi S, Imamura T, Maegawa H, et al. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Mol Cell Biol 2004;24:8778-8789
24. Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010;2:19-42
25. Horowitz MP, Greenamyre JT. Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis 2010;20(Suppl. 2):S551-S568
26. Welch KD, Davis TZ, Van Eden ME, Aust SD. Deleterious iron-mediated oxidation of biomolecules. Free Radic Biol Med 2002;32:577-583
27. Williams DM, Lee GR, Cartwright GE. The role of superoxide anion radical in the reduction of ferritin iron by xanthine oxidase. J Clin Invest 1974;53:665-667
28. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics 2009;2:2
29. Cantu D, Schaack J, Patel M. Oxidative inactivation of mitochondrial aco-nitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures. PLoS One 2009;4:e7095
30. Zou MH. Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat 2007;82:119-127
31. Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006;17:2664-2669
32. Nasu T, Kinomura M, Tanabe K, et al. Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol 2012;302:F1616-F1629
33. Chen Y, Yang S, Yao W, et al. Prostacyclin analogue beraprost inhibits cardiac fibroblast proliferation depending on prostacyclin receptor activation through a TGF (3-Smad signal pathway. PLoS One 2014;9:e98483
34. Nusing R, Goerig M, Habenicht AJ, Ullrich V. Selective eicosanoid formation during HL-60 macrophage differentiation. Regulation of thromboxane synthase. Eur J Biochem 1993;212:371-376
35. Sharma R, McDonald TS, Eng H, et al. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos 2013;41: 2148-2157
36. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820
37. Xiong W, Ferrell JE Jr. A positive-feedback-based bistable 'memory module' that governs a cell fate decision. Nature 2003;426:460-465
38. Burrill DR, Silver PA. Making cellular memories. Cell 2010;140:13-18
39. Macarthur BD, Ma'ayan A, Lemischka IR. Systems biology of stem cell fate and cellular reprogramming. Nat Rev Mol Cell Biol 2009;10:672-681
40. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-872
41. Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochondrial uncoupling proteins. Nature 2002;415:96-99
42. Mailloux RJ, McBride SL, Harper ME. Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Trends Biochem Sci 2013;38:592-602
43. Mailloux RJ, Seifert EL, Bouillaud F, Aguer C, Collins S, Harper ME. Glu-tathionylation acts as a control switch for uncoupling proteins UCP2 and UCP3. J Biol Chem 2011;286:21865-21875
44. Ban K, Kim KH, Cho CK, et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531
45. Paneni F, Mocharla P, Akhmedov A, et al. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res 2012;111:278-289
46. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006;55:798-805
47. Vincent AM, Russell JW, Sullivan KA, et al. SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp Neurol 2007; 208:216-227
48. Kowluru RA, Kowluru V, Xiong Y, Ho YS. Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radic Biol Med 2006;41:1191-1196
49. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615-1625
50. King MP, Attardi G. Isolation of human cell lines lacking mitochondrial DNA. Methods Enzymol 1996;264:304-313
51. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353: 2643-2653